A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

December 29, 2025

Study Completion Date

December 29, 2025

Conditions

Breast CancerHER2-positive

Interventions

DRUG

Zanidatamab

Given IV

DRUG

Letrozole

Given by PO

DRUG

Tamoxifen

Given by PO

Trial Locations (1)

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

Zymeworks BC Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER